May 1, 2005Psychosomatic Medicine
Lessons From SADHART, ENRICHD, and Other Trials
Key result
A review of SADHART and ENRICHD indicates that while sertraline and cognitive-behavioral therapy effectively treat depression in heart disease, they have not demonstrated a mortality benefit.
Population
Patients with cardiovascular disease and depression
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
Depression treatment in CVD should target symptoms without expecting mortality reduction; leaves open whether other interventions improve survival.
Structured PICO
P
Population
Patients with cardiovascular disease and depression
I
Intervention
Depression treatments (sertraline, cognitive-behavioral therapy)
While treatments like sertraline and CBT are effective for depression in cardiovascular patients, their impact on reducing cardiovascular morbidity and mortality remains unproven.
Limitations
- Difficulties in the definition and measurement of depression
- Complexities in the conduction of large-scale trials
- Ethical considerations surrounding the use of placebo
- Lack of certainty regarding the pathophysiologic link between depression and cardiovascular disease
- difficulties in the definition and measurement of depression
- complexities in the conduction of large-scale trials
- ethical considerations surrounding the use of placebo
- lack of certainty regarding the pathophysiologic link between depression and cardiovascular disease
Cite This Study
Joynt et al. (2005) conducted a review in Depression and cardiovascular disease. A review of SADHART and ENRICHD indicates that while sertraline and cognitive-behavioral therapy effectively treat depression in heart disease, they have not demonstrated a mortality benefit.